{"id":50786,"date":"2022-11-14T07:02:12","date_gmt":"2022-11-14T06:02:12","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/innate-pharma-reports-third-quarter-financial-results\/"},"modified":"2022-11-14T07:02:12","modified_gmt":"2022-11-14T06:02:12","slug":"innate-pharma-reports-third-quarter-financial-results","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/innate-pharma-reports-third-quarter-financial-results\/","title":{"rendered":"Innate Pharma Reports Third Quarter Financial Results"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<b><i>Preliminary data from ongoing Phase 2 TELLOMAK trial of lacutamab demonstrated clinical activity in mycosis fungoides, presented at EORTC-CLTG annual meeting<\/i><\/b>\n<\/li>\n<li>\n<b><i>Preliminary Sezary syndrome lacutamab Phase 2 data to be presented at ASH 2022 Annual Congress<\/i><\/b>\n<\/li>\n<li>\n<b><i>Innovative ANKET<\/i><\/b><i><b>\u2122<\/b><\/i><b><i> pipeline will be on display at ASH 2022 Annual Congress<\/i><\/b>\n<\/li>\n<li>\n<b><i>Cash position of \u20ac151.4 million<\/i><i><sup>1<\/sup><\/i><i> as of 30 September 2022, with anticipated cash runway into H2 2024<\/i><\/b>\n<\/li>\n<li>\n<b><i>Conference call to be held today at 2:00 p.m. CET \/ 8:00 a.m. ET<\/i><\/b>\n<\/li>\n<\/ul>\n<p>MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News:\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20221113005104\/en\/1245155\/4\/INNATEvertnoirDS.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20221113005104\/en\/1245155\/21\/INNATEvertnoirDS.jpg\"><\/a><\/p>\n<p>\nInnate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201c<b>Innate<\/b>\u201d or the \u201c<b>Company<\/b>\u201d) today announced its revenues and cash position for the first nine months of 2022.\n<\/p>\n<p>\n\u201c<i>Innate\u2019s strong financial position, innovative science and strategic collaborations enable us to progress a focused pipeline of antibodies, including several potentially first-in-class clinical and preclinical candidates, in cancers with high unmet medical need<\/i>.\u201d said <b>Mondher Mahjoubi, Chief Executive Officer of Innate Pharma<\/b>. \u201c<i>We are pleased to see that lacutamab continues to show clinical activity in mycosis fungoides. We look forward to sharing data from the Phase 2 TELLOMAK trial for lacutamab in S\u00e9zary syndrome at ASH, as well as shining the spotlight on our proprietary ANKET\u2122 platform, which demonstrates an important role in activating an anti-tumor response. Our third strategic pillar continues to advance, as part of our collaboration with AstraZeneca the PACIFIC-9 Phase 3 study of monalizumab in the early non-small cell lung cancer setting.<\/i>\u201d\n<\/p>\n<p>\n<b><i>Webcast and conference call will be held today at 2:00pm CET (8:00am ET).<\/i><\/b>\n<\/p>\n<p class=\"bwalignc\">\n<b>The live webcast will be available at the following link:<br \/>\n<br \/><\/b><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fevents.q4inc.com%2Fattendee%2F306131452&amp;esheet=52968157&amp;newsitemid=20221113005104&amp;lan=en-US&amp;anchor=https%3A%2F%2Fevents.q4inc.com%2Fattendee%2F306131452&amp;index=1&amp;md5=138e75d2c4536d3b9af3a138a94d9220\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/events.q4inc.com\/attendee\/306131452<\/a>\n<\/p>\n<p>\nParticipants may also join via telephone by registering in advance of the event at: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fregistrations.events%2Fdirect%2FQ4E60139&amp;esheet=52968157&amp;newsitemid=20221113005104&amp;lan=en-US&amp;anchor=https%3A%2F%2Fregistrations.events%2Fdirect%2FQ4E60139&amp;index=2&amp;md5=7ebfcc6f7e26ae0e60973ad98b04d85a\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/registrations.events\/direct\/Q4E60139<\/a>. Upon registration, participants will be provided with dial-in numbers, a direct event passcode and a unique registrant ID that they may use 10 minutes prior to the event start to access the call.\n<\/p>\n<p>\nThis information can also be found on the Investors section of the Innate Pharma website, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.innate-pharma.com&amp;esheet=52968157&amp;newsitemid=20221113005104&amp;lan=en-US&amp;anchor=www.innate-pharma.com&amp;index=3&amp;md5=0304b8dafad5cd2eb0364f1e29279125\" rel=\"nofollow noopener\" shape=\"rect\">www.innate-pharma.com<\/a>. A replay of the webcast will be available on the Company website for 90 days following the event.\n<\/p>\n<div class=\"bwpagebreakafter\">\n<\/div>\n<p>\n<b>Pipeline highlights:<\/b>\n<\/p>\n<p>\n<b><span class=\"bwuline\">Lacutamab (anti-KIR3DL2 antibody):<\/span><\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nPreliminary results from the Phase 2 TELLOMAK study were presented at the EORTC-CLTG (European Organisation for Research and Treatment of Cancer &#8211; Cutaneous Lymphoma Tumours Group) 2022 meeting on 23 September, confirming clinical activity and favorable safety profile of lacutamab in patients with mycosis fungoides who express KIR3DL2 and who were previously treated with at least two lines of systemic therapy. Results showed that lacutamab produced a global objective response rate (ORR) of 28.6% (95% confidence interval [CI], 13.8-50.0) in the KIR3DL2-expressing MF patients (n=21), including 2 complete responses and 4 partial responses.\n<\/li>\n<li>\nThe Company announced that it will report preliminary data from the Phase 2 TELLOMAK study in S\u00e9zary syndrome at the ASH (American Society of Hematology) 2022 Annual Congress on 10 December. The ASH abstract states that the preliminary data demonstrate that lacutamab showed clinical activity and a favorable safety profile. In the heavily pre-treated post-mogamulizumab patient population with an average of six prior lines of therapy, in the Intention to treat population (ITT) population, the global confirmed ORR was 21.6% (8\/37). Confirmed ORR in the skin was 35.1% (13\/37) and confirmed ORR in the blood was 37.8% (14\/37). Additional data will be presented at the ASH 2022 Annual Congress.\n<\/li>\n<li>\nOn 11 September, at the ESMO 2022 conference, the Company presented a poster on the ongoing lacutamab Phase 1b trial design in monotherapy in peripheral T-cell lymphoma (PTCL).\n<\/li>\n<li>\nTwo clinical trials are underway evaluating lacutamab in patients with KIR3DL2-expressing, relapsed\/refractory PTCL:<\/p>\n<ul class=\"bwlistcircle\">\n<li>\nPhase 1b trial: a Company-sponsored Phase 1b clinical trial to evaluate lacutamab as a monotherapy in patients with KIR3DL2-expressing relapsed PTCL.\n<\/li>\n<li>\nPhase 2 KILT (anti-KIR in T Cell Lymphoma) trial: The Lymphoma Study Association (LYSA) investigator-sponsored, randomized trial to evaluate lacutamab in combination with chemotherapy GEMOX (gemcitabine in combination with oxaliplatin) versus GEMOX alone in patients with KIR3DL2-expressing relapsed\/refractory PTCL.\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>\n<b><span class=\"bwuline\">ANKET\u2122 (Antibody-based NK cell Engager Therapeutics):<\/span><\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nAn <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.sciencedirect.com%2Fscience%2Farticle%2Fpii%2FS266637912200338X&amp;esheet=52968157&amp;newsitemid=20221113005104&amp;lan=en-US&amp;anchor=18+October+edition&amp;index=4&amp;md5=9866b4cc4d3d8b081247bd4271b6f277\" rel=\"nofollow noopener\" shape=\"rect\">18 October edition<\/a> of Cell Reports Medicine described the development of Innate\u2019s fit-for-purpose ANKET\u2122 antibody-based tetra-specific molecule to harness the antitumor functions of NK cells, boosting their capacity to proliferate, to accumulate at the tumor site and to kill tumor cells.\n<\/li>\n<li>\nProgress continues toward investigational new drug (IND) filing in 2023 for the CD20 targeted tetra-specific ANKET\u2122, IPH6501.\n<\/li>\n<li>\nSanofi will present two posters on SAR\u2019579\/IPH6101 and SAR\u2019514\/IPH6401 at the ASH 2022 Annual Congress on the 11 and 12 December:<\/p>\n<ul class=\"bwlistcircle\">\n<li>\nAn open-label, first-in-human, dose-escalation study of SAR443579 administered as single agent by intravenous infusion in patients with relapsed or refractory acute myeloid leukemia (R\/R AML), B-cell acute lymphoblastic leukemia (B-ALL) or high-risk myelodysplasia (HR-MDS)\n<\/li>\n<li>\nThe Novel Trifunctional Anti-BCMA NK Cell Engager SAR\u2019514 Has Potent in-Vitro and in-Vivo Anti-Myeloma Effect through Dual NK Cell Engagement\n<\/li>\n<\/ul>\n<\/li>\n<li>\nThe Phase 1\/2 clinical trial by Sanofi continues, evaluating IPH6101\/SAR\u2019579, the first NKp46\/CD16-based CD123-targeted ANKET\u2122 NK cell engager, in patients with relapsed or refractory acute myeloid leukemia (R\/R AML), B-cell acute lymphoblastic leukemia (B-ALL) or high-risk myelodysplastic syndrome (HR-MDS).\n<\/li>\n<li>\nIt was <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.innate-pharma.com%2Fmedia%2Fall-press-releases%2Fsecond-innate-pharma-nk-cell-engager-selected-sanofi-drug-candidate-development&amp;esheet=52968157&amp;newsitemid=20221113005104&amp;lan=en-US&amp;anchor=previously+announced&amp;index=5&amp;md5=b0960e45926d0a44481e26a5cb0694dc\" rel=\"nofollow noopener\" shape=\"rect\">previously announced<\/a> that Sanofi had made the decision to progress IPH6401\/SAR\u2019514 into investigational new drug (IND)-enabling studies. IPH6401\/SAR\u2019514 is a BCMA-targeting NK cell engager using Sanofi\u2019s proprietary CROSSODILE\u00ae multi-functional platform, which comprises the Cross-Over-Dual-Variable-Domain (CODV) format. It induces a dual targeting of the NK activating receptors, NKp46 and CD16, for an optimized NK cell activation, based on Innate\u2019s ANKET\u2122 proprietary platform.\n<\/li>\n<\/ul>\n<div class=\"bwpagebreakafter\">\n<\/div>\n<p>\n<b><span class=\"bwuline\">Monalizumab (anti-NKG2A antibody), partnered with AstraZeneca:<\/span><\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nInnate continues to see progress for monalizumab in the early non-small cell lung cancer setting, with the ongoing Phase 3 PACIFIC-9 study run by AstraZeneca.\n<\/li>\n<li>\nOn 12 September at the European Society for Medical Oncology (ESMO) 2022 congress, AstraZeneca presented an <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.innate-pharma.com%2Fsites%2Fdefault%2Ffiles%2FNeoCOAST%2520ESMO%2520Mini%2520Oral%2520Presentation_Final_0.pdf&amp;esheet=52968157&amp;newsitemid=20221113005104&amp;lan=en-US&amp;anchor=oral+presentation&amp;index=6&amp;md5=856e91f4d288e5f5cc4ce99134cfaf1d\" rel=\"nofollow noopener\" shape=\"rect\">oral presentation<\/a> on the Phase 2 NeoCOAST study assessing the safety and efficacy of neoadjuvant durvalumab in combination with chemotherapy and oleclumab (AstraZeneca\u2019s anti-CD73) or monalizumab and adjuvant treatment in patients with resectable, early-stage NSCLC.\n<\/li>\n<li>\nOn 1 August, Innate announced that a planned futility interim analysis of the Phase 3 INTERLINK-1 study sponsored by AstraZeneca did not meet a pre-defined threshold for efficacy. The company announced that, based on the result and the recommendation of an Independent Data Monitoring Committee, the study was to be discontinued. There were no new safety findings. AstraZeneca plan to share the data in due course. The INTERLINK-1 study, evaluated monalizumab in combination with cetuximab vs. cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck who have been previously treated with platinum-based chemotherapy and PD-(L)1 inhibitors.\n<\/li>\n<\/ul>\n<p>\n<b><span class=\"bwuline\">IPH5201 (anti-CD39), partnered with AstraZeneca:<\/span><\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nThe previously announced Phase 2 clinical trial conducted by Innate in lung cancer for IPH5201, an anti-CD39 blocking monoclonal antibody developed in collaboration with AstraZeneca, is in planning. The Company will present a poster of preclinical data supporting the rationale for the clinical trial at the 2022 ESMO Immuno-Oncology (IO) Annual Congress in December.\n<\/li>\n<li>\nAstraZeneca will present a poster entitled \u201cIPH5201 as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumours\u201d at the 2022 ESMO IO Annual Congress in December.\n<\/li>\n<\/ul>\n<div class=\"bwpagebreakafter\">\n<\/div>\n<p>\n<b><span class=\"bwuline\">IPH5301 (anti-CD73):<\/span><\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nThe investigator-sponsored Phase 1 trial of IPH5301 (CHANCES), in collaboration with Institut Paoli-Calmettes is ongoing. The trial will be conducted in two parts, Part 1, the dose escalation, followed by a Part 2 safety expansion study cohort. Part 2 will evaluate IPH5301 in combination with chemotherapy and trastuzumab in HER2+ cancer patients. The design of the Phase 1 study will be highlighted at the ESMO IO congress in December.\n<\/li>\n<\/ul>\n<p>\n<b>Corporate Update:<\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nOn May 03, Innate announced the commencement of an At-The-Market (ATM) program, pursuant to which it may, from time to time, offer and sell to eligible investors a total gross amount of up to $75 million American Depositary Shares (\u201cADS\u201d). Each ADS representing one ordinary share of Innate. As of September 30, 2022, the balance available under our May 2022 sales agreement remains at $75 million.\n<\/li>\n<\/ul>\n<p>\n<b>Financial Results:<\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nCash, cash equivalents and financial assets of the Company amounted to \u20ac151.4 million as of September 30, 2022. At the same date, financial liabilities amounted to \u20ac43.1 million.\n<\/li>\n<li>\nRevenues for the first nine months of 2022 amounted to \u20ac44.3 million (\u20ac10.3 million for the same period in 2021). For the nine-month period, ended September 30, 2022, revenue from collaboration and licensing agreements mainly results from the spreading of the payments received under our agreements with AstraZeneca and Sanofi.\n<\/li>\n<\/ul>\n<p>\n<b>About Innate Pharma:<\/b>\n<\/p>\n<p>\nInnate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.\n<\/p>\n<p>\nInnate Pharma\u2019s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.\n<\/p>\n<p>\nInnate is a pioneer in the understanding of Natural Killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A\/S, Sanofi, and a multi-products collaboration with AstraZeneca.\n<\/p>\n<p>\nHeadquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.\n<\/p>\n<p>\nLearn more about Innate Pharma at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.innate-pharma.com&amp;esheet=52968157&amp;newsitemid=20221113005104&amp;lan=en-US&amp;anchor=www.innate-pharma.com&amp;index=7&amp;md5=80df7f5d811e038bdf8a9992cc9c75db\" rel=\"nofollow noopener\" shape=\"rect\">www.innate-pharma.com<\/a>\n<\/p>\n<p>\n<b>Information about Innate Pharma shares:<\/b>\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignl bwcellpmargin\">\n<b>ISIN code<\/b>\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nFR0010331421\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignl bwcellpmargin\">\n<b>Ticker code<\/b>\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nEuronext: IPH Nasdaq: IPHA\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwalignl\" colspan=\"1\" rowspan=\"1\" style=\"height:17px;\">\n<p class=\"bwalignl bwcellpmargin\">\n<b>LEI<\/b>\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\" style=\"height:17px;\"><\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwalignl\" colspan=\"1\" rowspan=\"1\" style=\"height:17px;\">\n<p class=\"bwcellpmargin bwalignl\">\n9695002Y8420ZB8HJE29\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<div class=\"bwpagebreakafter\">\n<\/div>\n<p>\n<b>Disclaimer on forward-looking information and risk factors:<\/b>\n<\/p>\n<p>\nThis press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including \u201cbelieve,\u201d \u201cpotential,\u201d \u201cexpect\u201d and \u201cwill\u201d and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company\u2019s commercialization efforts and the Company\u2019s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties which could cause the company&#8217;s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (\u201cFacteurs de Risque&#8221;) section of the Universal Registration Document filed with the French Financial Markets Authority (\u201cAMF\u201d), which is available on the AMF website <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.amf-france.org&amp;esheet=52968157&amp;newsitemid=20221113005104&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.amf-france.org&amp;index=8&amp;md5=c6422017928ec19fc87ce6737d2909f7\" rel=\"nofollow noopener\" shape=\"rect\">http:\/\/www.amf-france.org<\/a> or on Innate Pharma\u2019s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (\u201cSEC\u201d), including the Company\u2019s Annual Report on Form 20-F for the year ended December 31, 2021, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.\n<\/p>\n<p>\nThis press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.\n<\/p>\n<p>\n<sup>1<\/sup> Including short term investments (\u20ac21.6 million) and non-current financial instruments (\u20ac34.3 million).\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>For additional information:<\/b>\n<\/p>\n<p>\n<b><span class=\"bwuline\">I<\/span><\/b><span class=\"bwuline\"><b>nvestors<\/b><\/span>\n<\/p>\n<p>\n<b>I<\/b><b>nnate Pharma<\/b><br \/>Henry Wheeler<br \/>\n<br \/>Tel.: +33 (0)4 84 90 32 88<br \/>\n<br \/><a target=\"_blank\" href=\"m&#97;&#105;&#x6c;&#x74;o:&#72;&#101;&#x6e;&#x72;y&#46;&#119;&#104;&#x65;&#x65;le&#114;&#x40;&#x69;&#x6e;n&#97;&#116;&#x65;&#x2d;&#x70;h&#97;&#114;&#x6d;&#x61;&#x2e;f&#114;\" rel=\"nofollow noopener\" shape=\"rect\">&#x48;&#101;n&#x72;&#121;&#46;&#x77;&#104;e&#x65;&#108;e&#x72;&#64;i&#x6e;&#110;a&#x74;&#101;-&#x70;&#104;a&#x72;&#109;a&#x2e;&#102;r<\/a>\n<\/p>\n<p>\n<b><span class=\"bwuline\">Media Relations<\/span><\/b>\n<\/p>\n<p>\n<b>N<\/b><b>ewCap<\/b><br \/>Arthur Rouill\u00e9<br \/>\n<br \/>Tel.: +33 (0)1 44 71 00 15<br \/>\n<br \/><a target=\"_blank\" href=\"ma&#105;&#108;&#116;&#x6f;&#x3a;&#x69;&#x6e;&#x6e;at&#101;&#64;&#110;&#x65;&#x77;&#x63;&#x61;&#x70;&#46;e&#117;\" rel=\"nofollow noopener\" shape=\"rect\">&#x69;&#x6e;&#110;a&#x74;&#x65;&#x40;&#110;e&#x77;&#x63;&#x61;&#112;&#46;&#x65;&#x75;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Preliminary data from ongoing Phase 2 TELLOMAK trial of lacutamab demonstrated clinical activity in mycosis fungoides, presented at EORTC-CLTG annual meeting Preliminary Sezary syndrome lacutamab Phase 2 data to be presented at ASH 2022 Annual Congress Innovative ANKET\u2122 pipeline will be on display at ASH 2022 Annual Congress Cash position of \u20ac151.4 million1 as of &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/innate-pharma-reports-third-quarter-financial-results\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50786","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Innate Pharma Reports Third Quarter Financial Results - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/innate-pharma-reports-third-quarter-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innate Pharma Reports Third Quarter Financial Results - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Preliminary data from ongoing Phase 2 TELLOMAK trial of lacutamab demonstrated clinical activity in mycosis fungoides, presented at EORTC-CLTG annual meeting Preliminary Sezary syndrome lacutamab Phase 2 data to be presented at ASH 2022 Annual Congress Innovative ANKET\u2122 pipeline will be on display at ASH 2022 Annual Congress Cash position of \u20ac151.4 million1 as of ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/innate-pharma-reports-third-quarter-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-14T06:02:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221113005104\/en\/1245155\/21\/INNATEvertnoirDS.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-reports-third-quarter-financial-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-reports-third-quarter-financial-results\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Innate Pharma Reports Third Quarter Financial Results\",\"datePublished\":\"2022-11-14T06:02:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-reports-third-quarter-financial-results\\\/\"},\"wordCount\":1856,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-reports-third-quarter-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221113005104\\\/en\\\/1245155\\\/21\\\/INNATEvertnoirDS.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-reports-third-quarter-financial-results\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-reports-third-quarter-financial-results\\\/\",\"name\":\"Innate Pharma Reports Third Quarter Financial Results - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-reports-third-quarter-financial-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-reports-third-quarter-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221113005104\\\/en\\\/1245155\\\/21\\\/INNATEvertnoirDS.jpg\",\"datePublished\":\"2022-11-14T06:02:12+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-reports-third-quarter-financial-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-reports-third-quarter-financial-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-reports-third-quarter-financial-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221113005104\\\/en\\\/1245155\\\/21\\\/INNATEvertnoirDS.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221113005104\\\/en\\\/1245155\\\/21\\\/INNATEvertnoirDS.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-reports-third-quarter-financial-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innate Pharma Reports Third Quarter Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Innate Pharma Reports Third Quarter Financial Results - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/innate-pharma-reports-third-quarter-financial-results\/","og_locale":"en_US","og_type":"article","og_title":"Innate Pharma Reports Third Quarter Financial Results - Pharma Trend","og_description":"Preliminary data from ongoing Phase 2 TELLOMAK trial of lacutamab demonstrated clinical activity in mycosis fungoides, presented at EORTC-CLTG annual meeting Preliminary Sezary syndrome lacutamab Phase 2 data to be presented at ASH 2022 Annual Congress Innovative ANKET\u2122 pipeline will be on display at ASH 2022 Annual Congress Cash position of \u20ac151.4 million1 as of ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/innate-pharma-reports-third-quarter-financial-results\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-14T06:02:12+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221113005104\/en\/1245155\/21\/INNATEvertnoirDS.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-reports-third-quarter-financial-results\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-reports-third-quarter-financial-results\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Innate Pharma Reports Third Quarter Financial Results","datePublished":"2022-11-14T06:02:12+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-reports-third-quarter-financial-results\/"},"wordCount":1856,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-reports-third-quarter-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221113005104\/en\/1245155\/21\/INNATEvertnoirDS.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-reports-third-quarter-financial-results\/","url":"https:\/\/pharma-trend.com\/en\/innate-pharma-reports-third-quarter-financial-results\/","name":"Innate Pharma Reports Third Quarter Financial Results - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-reports-third-quarter-financial-results\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-reports-third-quarter-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221113005104\/en\/1245155\/21\/INNATEvertnoirDS.jpg","datePublished":"2022-11-14T06:02:12+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-reports-third-quarter-financial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/innate-pharma-reports-third-quarter-financial-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-reports-third-quarter-financial-results\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221113005104\/en\/1245155\/21\/INNATEvertnoirDS.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221113005104\/en\/1245155\/21\/INNATEvertnoirDS.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-reports-third-quarter-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Innate Pharma Reports Third Quarter Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50786","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50786"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50786\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50786"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50786"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50786"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}